Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus (NCT02935673), a randomized phase 2 study. The primary outcome is Maximum Observed Plasma Concentration (Cmax) of JNJ-63549109 at Day 1.

2. Clinical Question

The study addressed two related questions in adults hospitalized with respiratory syncytial virus (RSV): how lumicitabine regimens affect antiviral activity, and how the drug is handled in this patient population. Its stated purpose also included characterizing pharmacokinetics and confirming a population pharmacokinetic model derived from healthy volunteers. The primary posted endpoint, however, is a pharmacokinetic measure rather than a direct measure of viral shedding or clinical recovery.

The broader study also assessed antiviral activity using nasal RSV shedding measured by a quantitative real-time reverse transcriptase-polymerase chain reaction assay. The registry record lists clinical outcomes and safety outcomes as secondary measures. The result discussed as primary therefore answers a narrower pharmacokinetic question; it should not be read as a direct estimate of antiviral activity or of a clinical treatment effect.

3. Trial Design

The registry describes a Phase 2b randomized, double-blind, placebo-controlled, parallel study of orally administered lumicitabine regimens in adults hospitalized with RSV. The listed intervention categories are lumicitabine and placebo. Randomization and double masking are features intended to reduce systematic differences in treatment assignment and outcome assessment, although the registry record does not report further details about the randomization procedure or how masking was maintained.

Regimen A was matching placebo, given as a loading dose followed by maintenance doses twice daily. Regimen B was the low-dose lumicitabine regimen: a 750 mg loading dose followed by nine 250 mg maintenance doses, administered twice daily. Regimen C was the high-dose regimen: a 1000 mg loading dose followed by nine 500 mg maintenance doses, administered twice daily. The high-dose regimen was listed for part 2, while placebo and the low-dose regimen were listed for both parts. The registry record does not report how participants were distributed between study parts.

Enrollment is listed as 49, and the study status is terminated. The listed study dates are 2016-10-25 for start and 2018-07-17 for primary completion. These record-level details describe the study's conduct and status; they do not by themselves explain why the study was terminated or establish whether every planned objective was completed. A reason for termination is not reported in the registry record.

The primary endpoint analysis is described as a pharmacokinetic analysis of the safety set, analyzed as treated. Participants had to receive at least one dose to enter that set, and the endpoint-specific count represents those evaluable for the measure. The primary outcome lists pooled analyses, but the registry record does not give further detail about the pooling procedure. The posted primary results give separate descriptive summaries for each lumicitabine regimen. No placebo value is listed for this primary pharmacokinetic endpoint.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 49 participants were randomized and treated (2 participants in Part 0, 36 participants in Part 1 and 11 participants in Part 2). Analyses were conducted on pooled groups across the 3 study parts.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Pharmacokinetic (PK) analysis was performed on safety set which included all participants who received at least 1 dose of study drug, analyzed as treated. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Analyses were conducted on pooled groups across the 3 study parts.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Maximum Observed Plasma Concentration (Cmax) of JNJ-63549109 at Day 1, measured over Day 1.

The primary endpoint is the maximum observed plasma concentration, or Cmax, of JNJ-63549109 on Day 1. JNJ-63549109 is identified in the registry record as the metabolized product of lumicitabine. The endpoint is measured in nanograms per milliliter and summarized as a mean with a standard deviation. It is a pharmacokinetic measure: it describes the peak observed concentration of the metabolite in plasma during the stated assessment period.

Maximum concentration is used to characterize exposure after drug administration. Comparing its descriptive distribution across dosing regimens can help describe whether the regimens are associated with different observed concentration levels. In this study, the posted values are 1845.0 nanograms per milliliter for the 750 mg loading dose / 250 mg maintenance dose regimen and 2801.0 nanograms per milliliter for the 1000 mg loading dose / 500 mg maintenance dose regimen. The corresponding numbers analyzed are 26 and 4, respectively. These are group summaries, not estimates of an individual participant's concentration.

The endpoint does not directly measure nasal viral shedding, symptom improvement, discharge readiness, or safety. Nor does a higher mean concentration alone establish a clinical benefit or harm. Interpretation depends on the endpoint's pharmacological role, the variability of the observations, and the small number analyzed in the high-dose group. The registry record does not report a confidence interval or a formal between-regimen test for this primary result, so the posted summaries support description rather than a precise inferential comparison.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary endpoint is continuous: each evaluable participant has a plasma concentration measurement, and the registry summarizes those measurements using a mean and standard deviation. The mean describes the central level of the observed group values. The standard deviation describes their spread around that mean. Neither statistic by itself describes how uncertain the estimated group mean is; that would ordinarily require an inferential measure such as a confidence interval, which is not reported for the primary endpoint.

What does a confidence interval convey?

In general, a confidence interval is a range produced by a statistical procedure that expresses uncertainty around an estimated quantity. A wide interval indicates that the data are compatible with a broader range of values than a narrow interval. For the posted hospital-stay comparisons, the intervals include values on both sides of no difference. That means the data do not determine the direction of a difference with precision. A confidence interval is not a guarantee that the true value lies within its bounds, and it does not establish that all values in the range are equally plausible.

The primary Cmax summaries do not include confidence intervals or a reported formal comparison. The group means can be read as descriptive estimates, while the standard deviations show that individual observations vary. In particular, the high-dose group has a large standard deviation relative to its mean and only 4 participants analyzed. The resulting summary is especially sensitive to the values observed in that small group. The registry record does not report a distributional analysis or a method for assessing the stability of that estimate.

How should the mean differences be read?

For the hospital-stay outcomes, the posted comparison is an unadjusted mean difference between the low-dose lumicitabine group and placebo. A negative estimate means the observed mean was lower in the low-dose group under the subtraction direction used for the comparison. It does not, on its own, establish that the regimen caused a shorter stay. The confidence intervals for both comparisons include zero and extend to estimates in the opposite direction. The reported unadjusted p-values are 0.534 and 0.879. These values do not resolve the uncertainty in the estimates, and they should not be interpreted as the probability that a treatment effect is absent.

The reported comparison method is an unadjusted recalculation from posted summary statistics. It is not a substitute for a sponsor's analysis plan or a reported adjusted model. The registry record lists no reported analyses for these secondary outcomes. No discrepancy is flagged between the recalculation and a sponsor-reported analysis, but the sponsor's own analysis is not reported in the registry record. The registry record also does not report whether models adjusted for baseline characteristics, site, or other covariates.

Why do small groups and variability matter?

Precision depends on both the amount of information and the variability in the observations. Small analyzed groups generally yield less precise estimates, while greater variation makes it harder to distinguish a group mean from random fluctuation. These issues are visible in the primary pharmacokinetic summaries and in the small event counts for the QT outcome. For a binary outcome such as whether a participant had an abnormality, the observed count is informative about what occurred in the analyzed group, but sparse counts provide limited resolution about the underlying frequency.

Hospital stay is a continuous duration measure. The reported standard deviations are large in relation to some group means, and the registry does not report a transformation, a robust method, or a time-to-event analysis for these mean comparisons. Duration data can be skewed and can include unusually long stays; in general, such features can make a mean and a conventional standard error sensitive to a few observations. The posted results do not establish whether these distributional concerns were examined. Over-dispersion, in general, means that observed variation is greater than a statistical model expects; if present and unaccounted for, uncertainty estimates can be too optimistic. The registry record does not report an over-dispersion assessment for these outcomes.

What do the planning illustrations mean?

The planning illustrations for the hospital-stay comparisons use the observed effect as a starting point and show scenarios for detecting 100%, 75%, and 50% of that observed effect. For the comparison of time from study treatment initiation to discharge, the listed participants per arm for 80% power are 281, 499, and 1,121 across those scenarios; for 90% power they are 376, 667, and 1,501. For time from admission to discharge, the listed participants per arm for 80% power are 3,141, 5,584, and 12,563; for 90% power they are 4,205, 7,475, and 16,818.

These are planning illustrations, not observed power and not the trial's original sample-size design. The stated assumptions are a two-sided significance level of 0.05, equal allocation between the compared groups, and a normal approximation. Because the effect to detect is based on an observed estimate, the illustrations inherit the uncertainty of that estimate. They should not be treated as evidence that the study had a particular probability of detecting an effect. The registry record does not report its original sample-size justification or planning assumptions.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("750 mg LD / 250 mg MD Lumicitabine", "1000 mg LD / 500 mg MD Lumicitabine")
n   <- c(26, 4)
m   <- c(1845, 2801)
sp  <- c(545.2, 1509)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  750 mg LD / 250 mg MD Lumicitabine  26  1845.000  545.200  1624.789  2065.211
CARM  1000 mg LD / 500 mg MD Lumicitabine  4  2801.000  1509.000  399.844  5202.156

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists 41 outcome measures and 2 analyses, with 34 secondary outcomes posted. The secondary outcomes span safety measures and clinical course, including adverse events, vital-sign and laboratory abnormalities, QT interval abnormalities, and several definitions of hospital duration or readiness for discharge. Testing many outcomes creates a multiplicity concern: even when no treatment effect exists, repeated statistical testing can produce apparently noteworthy findings by chance.

The registry record does not report a prespecified multiplicity adjustment, a testing hierarchy, or a distinction between confirmatory and exploratory secondary analyses. The secondary p-values shown are unadjusted. They should therefore not be interpreted as if each were the only test conducted. Nor does the record establish that the outcome set or analysis choices were fixed before the data were examined. Details of prespecification are not reported in the registry record.

Missing-data handling is also not reported in the registry record. The endpoint descriptions identify analyzed participants, but do not explain why some randomized participants may not appear in a particular outcome analysis, how missing measurements were handled, or whether any imputation or sensitivity analysis was used. An outcome-specific analysis count can differ from an overall enrollment figure because not all participants are necessarily evaluable for every measure; the reason for any such difference is not given in the record.

The primary pharmacokinetic population is described as the safety set, consisting of participants who received at least one dose, analyzed as treated. The registry record states that the endpoint-specific N denotes participants evaluable for that measure. This is not the same description as an intention-to-treat analysis of all randomized participants. The record does not report an intention-to-treat result for the primary endpoint, or a comparison adjusted for treatment assignment. Further details about exclusions, protocol deviations, and analysis-population rules are not reported in the registry record.

Likewise, the registry record does not report the original sample-size justification, interim analyses, or the full statistical analysis plan. Those details cannot be inferred from the planning illustrations, which are retrospective illustrations based on observed effects rather than the trial's design. These omissions limit assessment of whether the posted analyses were prespecified and how robust they are to missing information or alternative analytic choices.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pancytopenia (16.7%), cardiac failure (6.2%), pneumonia (6.2%), thermal burn (6.2%), intestinal obstruction (3.7%).

The registry reports participants with serious adverse events in each treatment group: 2 of 16 for placebo, 4 of 27 for the 750 mg loading dose / 250 mg maintenance dose regimen, and 1 of 6 for the 1000 mg loading dose / 500 mg maintenance dose regimen. It reports no deaths in any group. For other adverse events, the posted counts are 6 of 16, 17 of 27, and 5 of 6, respectively. These counts describe what was recorded in the groups at risk; they do not establish that treatment caused an event or that groups differ in risk.

The registry lists Pancytopenia at 16.7%, Cardiac Failure, Pneumonia, and Thermal Burn at 6.2% each, and Intestinal Obstruction and Influenza at 3.7% each among the top serious adverse event terms. The record does not give enough context in this listing to interpret these percentages as comparative treatment effects. Small group sizes, the range of event types, and the absence of a reported adjusted safety comparison limit conclusions. The figures are descriptive safety information, not a basis for declaring a regimen safer or less safe.

13. What the Result Does, and Does Not, Mean

The posted results establish what was recorded for the analyzed participants, not what would necessarily occur in a broader population. For the primary endpoint, they show mean Day 1 concentrations of JNJ-63549109 in the two active-regimen groups, with substantial variability and a particularly small analyzed high-dose group. They do not supply a formal inferential comparison, a confidence interval, or a placebo value for Cmax. The result therefore supports a limited pharmacokinetic description, not a definitive claim that the regimens differ.

The secondary hospital-stay comparisons show estimates with wide confidence intervals that include values in both directions. The QT result is based on few observed abnormalities. These findings do not establish that the regimens shorten or lengthen hospitalization, change QT risk, or have no effect on those outcomes. A non-significant p-value is not proof of no effect, and a point estimate alone is not proof of a treatment effect.

These results also do not answer every question named in the study purpose. Although the study's stated objective includes antiviral activity assessed using nasal RSV shedding, the primary posted endpoint analyzed is pharmacokinetic. The registry record does not report a numerical result for that viral-shedding measure in the information summarized by the posted results. Findings for outcomes without posted values are not reported in the registry record.

The study was terminated, but the record does not report the reason. Termination alone does not explain whether the decision was related to safety, efficacy, recruitment, operational issues, or another cause. It should not be treated as evidence for any particular explanation. The record also does not report the original sample-size rationale or full analysis plan.

Overall, the posted data permit careful description of measured concentrations, selected secondary outcomes, and reported adverse events. They do not warrant a broad conclusion about antiviral efficacy, clinical benefit, or comparative safety. Interpretation must remain bounded by the outcome actually measured, the analyzed group sizes, the precision of the estimates, and the information absent from the registry record.

14. Why This Trial Matters Statistically

This trial illustrates why the clinical question and the endpoint actually analyzed need to be kept separate. The study's stated goals include antiviral activity and clinical outcomes in hospitalized adults with RSV, but the posted primary result is a pharmacokinetic measure of a lumicitabine metabolite. Cmax can characterize exposure, yet it is not itself a measure of viral shedding, recovery, or discharge. That distinction matters when translating a numerical result into a clinical interpretation.

It also illustrates the difference between descriptive summaries and comparative inference. The primary means and standard deviations show observed concentration levels and variability, but the record does not report a formal comparison or confidence interval for that endpoint. For the available secondary comparisons, confidence intervals are broad and cross the no-difference value. The data therefore communicate uncertainty as well as the observed estimates. A single point estimate or p-value cannot replace that fuller reading.

Small analyzed groups are especially important for interpreting the high-dose pharmacokinetic result and sparse safety outcomes. When group sizes are limited, individual observations can have a substantial influence on the mean or observed event count, and estimates may be imprecise. This is not a claim that the posted observations are invalid; it is a reason to avoid treating them as stable estimates of effects in a wider population.

Finally, the registry record makes visible the importance of reporting analytic plans, missing-data handling, multiplicity decisions, and reasons for study termination. Without those details, readers cannot fully assess how outcomes were selected or how robust the findings are to analytic choices. The study is therefore a useful example of how registry results can inform statistical reading while still leaving important inferential questions unresolved.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to the posted results. First, the primary endpoint is a Day 1 metabolite concentration, whereas the study purpose also includes antiviral activity and clinical outcomes. The posted primary summaries do not directly answer those broader questions. A numerical result for nasal RSV shedding is not reported in the registry record summarized by the posted results.

Second, the primary endpoint results are descriptive. The record provides group means, standard deviations, and analyzed counts but no primary confidence interval or formal between-regimen test. The high-dose group has 4 participants analyzed, making its mean and spread especially sensitive to individual observations. The record does not report a method to assess this sensitivity.

Third, the secondary hospital-stay estimates are imprecise, with confidence intervals extending in both directions. The registry record does not report a distributional assessment, a covariate-adjusted model, or a sensitivity analysis for these duration outcomes. The QT comparison is based on few events. The secondary p-values are unadjusted, and a multiplicity strategy is not reported.

Fourth, the registry record does not report how missing outcome measurements were handled, why the analysis counts differ by outcome, or the full rules for analysis populations beyond the safety-set description for the primary pharmacokinetic analysis. It also does not report the original sample-size justification, interim analyses, or the full statistical analysis plan. These absences limit evaluation of prespecification and robustness.

Finally, the study is marked terminated, but the reason for termination is not reported in the registry record. No explanation should be inferred from status alone. Taken together, these limitations mean the posted results are best read as limited descriptions of selected outcomes, rather than as a complete account of the planned clinical and antiviral questions.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus — NCT02935673.
• Registry record last updated 2019-12-24; status last verified 2019-12.
• Results first posted 2019-12-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry describes NCT02935673 as a randomized, double-blind, placebo-controlled Phase 2b study of oral lumicitabine regimens in adults hospitalized with RSV. The study is listed as terminated, with enrollment of 49 and primary completion dated 2018-07-17. Its primary posted endpoint is Day 1 maximum observed plasma concentration of JNJ-63549109, the metabolized product of lumicitabine.

The primary result reports descriptive Cmax summaries for the two active regimens. Secondary results include selected hospital-stay, QT, and safety outcomes. The primary pharmacokinetic result has no posted formal comparison, while the available secondary comparisons are unadjusted and have limited precision. The registry record does not report a reason for termination, the original sample-size justification, or a full statistical analysis plan. The results support cautious description, not broad claims about antiviral or clinical effects.